Loading
A phase 3 trial testing Zipalertinib in non-small-cell lung cancer, active and no longer recruiting.
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumours) is a phase 3 interventional study registered as NCT05973773, led by Taiho Oncology, and active but no longer recruiting on the registry. Official title: Randomised, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. Planned enrolment is 285 participants (actual). The study started in 2023-12-18 and primary completion is expected in 2027-05-27. No results have been posted on ClinicalTrials.gov.
Shares Taiho Oncology (Otsuka), Zipalertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Zipalertinib, EGFR-mutated non-small-cell lung cancer.
Shares Zipalertinib, Non-small-cell lung cancer.